Hikma to pay $115M in cash, $35M in donations to settle opioid claims
London-based Hikma Pharmaceuticals has reached an agreement to settle allegations brought against the company by US states and local governments for the manufacturing and sale of opioids.
Under the agreement, Hikma will pay up to $115 million in cash and $35 million in donations of Hikma’s naloxone, which reverses the effects of an overdose. But the deal still depends on the number of states and local governments that decide to opt in to Hikma’s proposition. The company added that the agreement isn’t an admission of wrongdoing and will continue to fight in court any lawsuits the deal doesn’t resolve.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.